Wednesday, March 03, 2021 7:06:49 AM
March 03, 2021 07:00 AM Eastern Standard Time
CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its clinical product candidate, cavrotolimod (AST-008), for the treatment of patients with Merkel cell carcinoma (MCC).
“We are excited to have been granted Orphan Drug Designation by the FDA for cavrotolimod for MCC,” said Dr. Douglas Feltner, Chief Medical Officer of Exicure. “This designation marks significant progress toward our goal of fulfilling the unmet medical need and finding a treatment for Merkel cell carcinoma patients.”
Exicure previously announced that the FDA granted two Fast Track designations for cavrotolimod (AST-008) for MCC and cutaneous squamous cell carcinoma (CSCC), both in the advanced/metastatic setting after progression on anti-PD-1/PD-L1 antibodies.
About Orphan Drug Designation
Orphan Drug Designation is a designation granted by the FDA which provides orphan status to drugs or biologics which are intended to treat rare diseases or disorders that affect fewer than 200,000 people in the United States. This designation provides the sponsor of the drug certain incentives, including tax credits for qualified clinical trials and fee waivers. Orphan Drug Designation confers eligibility for seven years of market exclusivity to an orphan drug post-approval, subject to a receipt by the FDA of marketing approval.
https://www.otcmarkets.com/stock/XCUR/news/story?e&id=1827806
Recent XCUR News
- Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K • Business Wire • 04/22/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 05:15:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 11:36:01 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 03/04/2024 10:37:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 09:16:37 PM
- Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis • Business Wire • 02/05/2024 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 09:16:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/01/2023 11:14:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/01/2023 09:21:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2023 09:19:44 PM
- Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q • Business Wire • 11/28/2023 09:01:00 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 09:28:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2023 09:03:29 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 09/29/2023 09:05:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/27/2023 09:25:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 09:03:38 PM
- Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors • Business Wire • 08/23/2023 01:48:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/23/2023 01:29:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/18/2023 10:09:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 08:33:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/11/2023 08:18:03 PM
- Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update • Business Wire • 08/11/2023 08:01:00 PM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM